Drugs

PI3K Inhibitor Fails to Pass Muster With FDA Advisory Committee

Posted on: Sep 23, 2022   |   Posted by: Master Doctor

PI3K Inhibitor Fails to Pass Muster With FDA Advisory Committee

The FDA's Oncologic Drugs Advisory Committee made a clean sweep of its 2-day meeting, deciding that the PI3K inhibitor duvelisib does not offer a favorable risk-benefit ratio...

Continue reading ...